[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,002,545
  • Shares Outstanding, K 115,821
  • Annual Sales, $ 655,350 K
  • Annual Income, $ -136,230 K
  • EBIT $ -183 M
  • EBITDA $ -192 M
  • 60-Month Beta 0.94
  • Price/Sales 3.07
  • Price/Cash Flow N/A
  • Price/Book 6.21

Options Overview Details

View History
  • Implied Volatility 71.32% (-0.55%)
  • Historical Volatility 87.40%
  • IV Percentile 47%
  • IV Rank 22.76%
  • IV High 152.45% on 03/18/26
  • IV Low 47.41% on 05/21/26
  • Expected Move (DTE 7) 1.36 (7.87%)
  • Put/Call Vol Ratio 1.44
  • Today's Volume 88
  • Volume Avg (30-Day) 568
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 21,450
  • Open Int (30-Day) 23,500
  • Expected Range 15.93 to 18.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.30
  • Number of Estimates 3
  • High Estimate $-0.23
  • Low Estimate $-0.40
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.43 +27.77%
on 06/23/26
18.35 -6.49%
on 06/15/26
+0.51 (+3.06%)
since 06/10/26
3-Month
10.40 +65.00%
on 04/13/26
18.92 -9.30%
on 05/11/26
+6.58 (+62.19%)
since 04/10/26
52-Week
9.82 +74.75%
on 02/09/26
18.92 -9.30%
on 05/11/26
-1.30 (-7.04%)
since 07/10/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).  Such investors are advised...

NVCR : 17.16 (-0.75%)
Novocure to Report Second Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...

NVCR : 17.16 (-0.75%)
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with...

NVCR : 17.16 (-0.75%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised...

NVCR : 17.16 (-0.75%)
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NASDAQ:...

NVCR : 17.16 (-0.75%)
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday...

NVCR : 17.16 (-0.75%)
Stocks Sharply Higher as US-Iran Peace Deal Eases Inflation Risks

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +1.08%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.48%. September E-mini...

ALK : 50.00 (-0.28%)
SNDK : 1,804.52 (-2.89%)
ADI : 388.74 (-1.24%)
SLB : 47.63 (+0.84%)
OXY : 52.54 (+0.46%)
NVCR : 17.16 (-0.75%)
FANG : 182.00 (-2.47%)
AMD : 542.00 (-0.86%)
VRT : 321.20 (-0.84%)
CTSH : 43.58 (+0.41%)
SPY : 751.77 (+0.01%)
MU : 973.82 (-1.80%)
Stocks Supported as Geopolitical Risks Recede

The S&P 500 Index ($SPX ) (SPY ) today is up +0.99%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.61%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.16%. September E-mini S&P futures...

ALK : 50.00 (-0.28%)
SNDK : 1,804.52 (-2.89%)
ADI : 388.74 (-1.24%)
SLB : 47.63 (+0.84%)
OXY : 52.54 (+0.46%)
NVCR : 17.16 (-0.75%)
FANG : 182.00 (-2.47%)
CTSH : 43.58 (+0.41%)
SPY : 751.77 (+0.01%)
MU : 973.82 (-1.80%)
BKR : 57.20 (-0.66%)
HURN : 102.51 (unch)
Stocks Rally as President Trump Signs a Preliminary Deal to End the US-Iran War

The S&P 500 Index ($SPX ) (SPY ) today is up +0.73%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.62%. June E-mini S&P futures (ESM26...

ALK : 50.00 (-0.28%)
AMAT : 574.00 (-2.49%)
UAL : 128.82 (-0.18%)
SNDK : 1,804.52 (-2.89%)
ADI : 388.74 (-1.24%)
TXN : 304.66 (-1.26%)
$IUXX : 29,727.10 (+1.62%)
ZNU26 : 109-055 (-0.09%)
NVCR : 17.16 (-0.75%)
ESU26 : 7,589.00 (unch)
FDS : 241.90 (-2.39%)
NCLH : 19.75 (-0.03%)
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start of...

NVCR : 17.16 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 18.64
2nd Resistance Point 18.32
1st Resistance Point 17.81
Last Price 17.16
1st Support Level 16.98
2nd Support Level 16.66
3rd Support Level 16.15

See More

52-Week High 18.92
Last Price 17.16
Fibonacci 61.8% 15.44
Fibonacci 50% 14.37
Fibonacci 38.2% 13.30
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.